Over the past 25 years, Ron has started and led a number of successful companies, including two NASDAQ-listed companies, CellPro (CPRO) and Xcyte Therapies (XCYT). He has extensive experience in all aspects of drug development from discovery through animal testing, toxicology, manufacturing, and clinical studies. He has B.S., Biology from Stanford University, an M.D. from Yale, and is boarded in internal medicine and medical oncology.

Maura has over 20 years of experience in developing biotechnology drugs, including small molecules, peptides, and proteins. She has participated in discovery, animal studies and toxicology, manufacturing, and regulatory activities. She has held senior positions at Somatogen, Baxter International, Dendreon, VentiRx, Metradora, and Baxter. Maura has a B.S. from Ripon College, and a PhD in Biochemistry from the University of Colorado.

Raj has over 20 years in the development and manufacturing of biotech drugs, including small molecules, peptides, and proteins. He has participated in the design of manufacturing processes, drug assays, and managed by the production of pharmaceuticals. He held senior development, manufacturing, and operations positions at Xcyte Therapies, Trubion, and Alder Pharmaceuticals. Raj has a PhD (University of Georgia) and MBA (University of Washington).

Chris is an immunologist with expertise in inflammation. He has participated in the development of several anti-inflammatory drugs, including peptides and proteins. He has held senior positions at Bristol Myers Squibb, Zymogenetics, Immune Design Corporation, and currently serves as President of TriaBio, which is developing vaccines. He has a Ph.D. in Biochemistry from the University of Washington, where also did his postdoctoral training.

Greg is a trained immunologist, who has over 25 years of experience in drug development in a variety of clinical areas, including inflammation and immunology. He has considerable expertise in testing drugs in animals and managing and conducting toxicology studies. He held senior management positions at ICOS and VentiRx. Greg received his B.S. and M.S. from Washington State University, and a Ph.D. from Oregon Health Sciences University.

Curt has more than 25 years of experience in both clinical development and regulatory affairs. He started his biotech career at the FDA where he was responsible for the review of several drugs. He then moved to Intarcica Therapeutics, and has held senior positions at RRD International and Quintiles, two regulatory advisory companies. He hold a B.S. (Grinnell College), M.D. (University of Colorado), and completed rheumatology training at the NIH.

Margaret is an award winning principal scientist, who has participated in the design and development of a number of anti-inflammatory drugs, including peptides and proteins. She has held laboratory positions at Zymogenetics, Viagene, and Hybritech. She received her Ph.D. in Protein Chemistry from the University of Texas, and then performed postdoctoral training at University of California San Diego and the Scripps Research Institute.

Eli is a CPA with over 10 years of experience at major accounting firms and followed by finance and business development experience in biotechnology. He was an accountant at Deloitte and Touche and Ernst and Young, and hen moved to a biotech company focusing on business development, and financing. He has a B.A. in Finance Administration from the University of Washington and a Master Degree, Accounting from Seattle University.

Dr. Terketaub is one of the leading experts on gout. He has played a major role in in the design and execution of major clinical trials in gout. His lab is actively involved in studying the pathophysiological mechanisms of gout. He is a member of the faculty at the University of California San Diego School of Medicine, and holds D.C.S. and M.D. degrees (McGill University) and completed rheumatology training at the University of Montreal.